The Calmer Co Completes $1.82 Million Rights Issue with Director Backing
3 min read
11:40am on Wednesday 2nd of September, 2026 AEST ~11am, 2nd Sept, 26
The Calmer Co International Limited has closed a renounceable rights issue, raising $1.82 million before costs with full director participation. The capital will support inventory build, retail expansion with Coles, and ongoing strategic partnerships in kava supply and manufacturing.
- Renounceable rights issue raises $1.82 million
- Over 1.8 billion shares and 945 million options issued
- Directors and management fully subscribe to entitlements
- Convertible note holders convert $365,000 reducing debt
- Funds to expand Coles product range and inventory
Capital Raise Completes with Strong Insider Support
The Calmer Co International Limited (ASX:CCO) has successfully closed its renounceable rights issue, securing $1.82 million before costs. The company will issue approximately 1.8 billion new shares alongside 945 million options exercisable at $0.002, expiring in February 2029. Eligible directors and management took up their full entitlements, signalling confidence in the company’s growth prospects.
The rights issue included applications from convertible note holders totalling $365,000, which reduces outstanding convertible notes to $1.035 million. These notes are set to be redeemed and cancelled, with ongoing discussions underway to place the remaining shortfall over the next three months.
Proceeds Target Inventory and Retail Expansion
Net proceeds from the offer are earmarked for building inventory for The Calmer Co’s wholesale channel and expanding the retail presence of its flagship FZZR® brand within Coles stores. The company expects its new FZZR® products to debut in Coles outlets from October 2026, aiming to capture a larger share of the fast-growing natural beverage market.
Alongside retail expansion, funds will support general working capital needs as The Calmer Co consolidates recent business developments.
Strategic Partnerships Underpin Growth Pipeline
The capital raise coincides with several strategic agreements that could materially influence The Calmer Co’s trajectory. The company has executed a Heads of Agreement with Kaiming Agro Processing to develop a manufacturing and sales alliance, leveraging advanced extraction technology to scale production of botanical extracts.
Additionally, The Calmer Co has secured a long-term supply agreement with a leading Pacific-based supplier of premium noble kava sourced from Papua New Guinea and Vanuatu. This deal complements the company’s existing sourcing network and supports its manufacturing capacity.
Crucially, the company holds exclusive distribution rights for kava extract ingredients with potential sales of up to $25 million over three years, underpinning a significant revenue stream across key markets.
Next Steps and Market Positioning
New shares and options are expected to be issued on 2 September 2026, with the board continuing to work closely with lead manager Mahe Capital on placing the remaining shortfall. The company’s focus on higher-margin sales channels and strategic partnerships aims to drive sustainable growth amid competitive natural beverage markets.
Bottom Line?
The Calmer Co’s successful capital raise and strategic deals position it to accelerate retail expansion and strengthen its supply chain, though execution of shortfall placement and partnership outcomes remain key near-term catalysts.
Questions in the middle?
- Will the company fully place the remaining shortfall in the coming months?
- How quickly will expanded Coles distribution translate into sustainable sales growth?
- Can strategic manufacturing and supply agreements deliver on projected revenue targets?
